Sunday, December 21, 2014 5:37:56 PM
"wholly fabricated story"
This was in relation to an accusation of fraud communicated to who knows how many third parties then found its way public. I'm sure you agree -- somebody who confesses by using the phrase "wholly fabricated story" when accusing a company of fraud may find him or herself in hot water.
It would be like calling the police and saying the man next door is a serial killer then when the police come over you say, "Oh, that phone call? That was a wholly fabricated story. The dude next door is innocent. I made it up."
In this country, opinions and mistakes are fine, but knowingly making up crime stories, then confessing that you knew they were false and "wholly fabricated" them can get you in trouble civilly and perhaps even more so criminally. This is perhaps even more true when referring to a public securities. Now imagine if that public security collapsed 31% while that "wholly fabricated story" was being circulated?
Again, not referring to any IHUB posters.
The SwingTrade Portfolio is up 42.1% YTD through 8/8/2014, 83.5% in 2013, and 537.4% since inception.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=105141243
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM